SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Sign Up to like & getrecommendations! Published in 2020 at "iScience"
DOI: 10.1016/j.isci.2020.101832
Abstract: Summary Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies… read more here.
Keywords: response tepotinib; influences therapeutic; shp2 inhibition; inhibition influences ... See more keywords
Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14205
Abstract: In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping… read more here.
Keywords: intolerable peripheral; capmatinib successfully; peripheral edema; edema ... See more keywords
Abstract 6776: Spatial transcriptomics of response to tepotinib treatment in a patient with NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6776
Abstract: Background: While cancer therapies are becoming increasingly more targeted, our understanding of the genomic changes occurring during these treatments is lacking. Moreover, the tumoral heterogeneity and its spatial distribution remain important obstacles in predicting tumor… read more here.
Keywords: tumor; patient; treatment; response ... See more keywords
Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20541
Abstract: e20541Background: Approximately 3-4% of lung adenocarcinomas express a truncated form of c-Met (c-Metex14) due to mutation-induced exon 14 skipping. c-Metex14 accumulates on the cell surface and is constitutively active with the ability to drive NSCLC.… read more here.
Keywords: lung adenocarcinoma; inhibitor tepotinib; tepotinib; exon skipping ... See more keywords
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9084
Abstract: 9084 Background: Brain metastases (BMs) are reported in 20–40% of pts with METex14 skipping NSCLC and present a high unmet need with poor prognosis. Tepotinib is a highly selective MET inhibitor that has demonstrated intracranial… read more here.
Keywords: tepotinib; skipping nsclc; intracranial activity; activity ... See more keywords
Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.tps9136
Abstract: TPS9136 Background: METamp is a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). METamp occurs in ̃30% of patients who progress on EGFR TKI therapy as measured using fluorescence in situ hybridization (FISH).… read more here.
Keywords: tepotinib; egfr mutant; study; resistance ... See more keywords
Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms231911809
Abstract: The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However, drug-induced pneumonitis is an uncommon but threatening adverse effect… read more here.
Keywords: lung cancer; non small; small cell; induced pneumonitis ... See more keywords